Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE vs AMMONUL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphate supplementation to correct hypophosphatemia; acts as a buffer and is essential for cellular energy metabolism (ATP), bone mineralization, and acid-base balance.
Ammonul (sodium phenylacetate and sodium benzoate) provides an alternative pathway for nitrogen excretion. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Benzoate conjugates with glycine to form hippurate, which is also excreted renally. This reduces ammonia levels in patients with urea cycle disorders.
Treatment of hypophosphatemia,Total parenteral nutrition (TPN) additive,Phosphate replacement in patients with phosphate depletion
FDA: Adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle disorders.,Off-label: Management of hyperammonemia due to other causes (e.g., valproate toxicity, organic acidemias).
IV: 2.5-5 mmol phosphate/kg body weight over 24 hours; typical dose 10-30 mmol phosphate over 4-6 hours; do not exceed 60 mmol phosphate/day.
For acute hyperammonemia: 2.5 g/m² IV over 90 minutes, followed by continuous IV infusion at 2.5 g/m² over 24 hours. For maintenance: 2.5 g/m² IV or oral every 6 hours.
Phosphate: 3-4 hours in healthy adults; prolonged with renal impairment. Potassium: short distribution half-life (~1-1.5 hours); no true terminal half-life due to tight regulation.
Phenylacetate: 0.5-1 hour; phenylacetylglutamine: 1-2 hours. Clinical context: rapid clearance; requires continuous IV infusion for sustained effect.
Phosphate is freely filtered by the glomerulus and reabsorbed in the proximal tubule; excess is excreted renally. No significant hepatic metabolism.
Sodium phenylacetate is metabolized via conjugation with glutamine (by glutamine N-phenylacetyltransferase) to form phenylacetylglutamine. Sodium benzoate is metabolized via conjugation with glycine (by benzoyl-Co A:glycine N-acyltransferase) to form hippurate. Both conjugates are rapidly excreted by the kidneys.
Renal: >90% of phosphate is reabsorbed or excreted by the kidneys; potassium is primarily excreted renally. Fecal elimination accounts for <10% of total phosphate loss.
Renal: >80% (primarily as phenylacetylglutamine). Biliary/fecal: <5%.
Phosphate: 10-15% bound to serum proteins (albumin and immunoglobulins). Potassium: <5% protein bound.
Phenylacetate: 82% bound to albumin; phenylacetylglutamine: 51% bound.
Phosphate: 0.15-0.3 L/kg (primarily extracellular fluid). Potassium: 0.5-0.7 L/kg (distributes into intracellular space).
Phenylacetate: 0.3-0.5 L/kg; phenylacetylglutamine: 0.1-0.2 L/kg. Indicates distribution primarily in extracellular fluid.
Intravenous: 100% bioavailability. Oral (not applicable for this formulation): 60-70% for phosphate salts; potassium salts >90%.
Oral: Not available; sodium phenylacetate/sodium benzoate is administered intravenously only.
GFR <30 m L/min: initiate at 50% of standard dose and titrate based on serum phosphate and potassium levels; avoid if GFR <15 m L/min unless severe hypophosphatemia.
Contraindicated in severe renal insufficiency (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-50 m L/min): reduce dose by 50%. For mild impairment (Cr Cl 50-80 m L/min): no adjustment needed.
No specific Child-Pugh based recommendations; use with caution in severe hepatic impairment due to potential for electrolyte disturbances.
No specific guidelines based on Child-Pugh; use with caution in severe hepatic impairment. Monitor ammonia levels.
IV: 0.5-1 mmol phosphate/kg over 12-24 hours; monitor serum phosphate and potassium closely; do not exceed 5 mmol/kg/day.
Same weight-based area (2.5 g/m²) as adults. For neonates and infants, dosage calculated per body surface area. Administration route and frequency identical to adults.
Initiate at lower end of dosing range; monitor renal function and serum electrolytes more frequently due to age-related decline in GFR.
No specific dose adjustment; use caution due to age-related renal decline. Monitor renal function and ammonia levels.
None
Ammonul must be administered with arginine to prevent arginine deficiency and worsening hyperammonemia. Neurotoxicity (including seizures, cerebral edema, and death) may occur if not properly monitored. Extravasation can cause severe tissue necrosis; ensure proper IV access.
Hyperphosphatemia, especially in renal impairment,Hypocalcemia due to precipitation with calcium,Monitor serum calcium, phosphate, and renal function,Avoid extravasation (may cause tissue necrosis),Not for IV push; give as slow infusion
Monitor plasma ammonia levels, electrolytes, and blood counts closely.,Risk of hypernatremia (high sodium load); adjust fluid and sodium intake.,Extravasation risk: administer through a central line if possible; treat extravasation immediately.,May cause hyperventilation and metabolic acidosis.,Use with caution in patients with hepatic or renal impairment.,Contains sodium benzoate; possible hypersensitivity reactions.
Hyperphosphatemia,Hypocalcemia,Renal failure (unless on dialysis),Patients with known hypersensitivity to any component
Known hypersensitivity to any component of Ammonul.,Pre-existing severe hypernatremia.,Concomitant use with other drugs containing sodium benzoate or sodium phenylacetate.
Avoid high-phosphate foods (e.g., dairy, nuts, seeds, whole grains, cola) and high-potassium foods (e.g., bananas, oranges, potatoes, spinach) unless prescribed. Limit intake of calcium-rich foods if calcium levels are low.
Take with food or meals to reduce gastrointestinal distress. Avoid high-protein supplements or foods that may increase ammonia levels; dietary protein restriction should be managed by a dietitian.
FDA Pregnancy Category C. No adequate studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second/third trimesters: may cause hypocalcemia, electrolyte imbalances in fetus; avoid prolonged use.
Pregnancy Category C. No adequate human studies; in animal studies, sodium phenylacetate/sodium benzoate caused fetal toxicity at maternally toxic doses. First trimester: potential risk unknown; second/third trimester: may cause maternal ammonia accumulation if subtherapeutic, but drug is essential for urea cycle disorders. Risk of untreated hyperammonemia outweighs potential teratogenic risk.
Excretion in human milk unknown; M/P ratio not determined. Use with caution, weighing benefit against potential risk of electrolyte disturbances in the nursing infant.
No human data on excretion in breast milk; M/P ratio unknown. Caution advised; consider risk of infant hyperammonemia vs. benefit of breastfeeding.
Increased plasma volume may require higher doses to achieve therapeutic levels; monitor serum electrolytes closely to avoid hyperphosphatemia or hypocalcemia. No standard dose adjustment established.
Monitor ammonia levels closely; pregnancy may increase metabolic demands. Dose adjustments based on ammonia levels: usual dose is weight-based (e.g., 5.5 g/m²/day for sodium phenylacetate/sodium benzoate). Consider increased clearance during pregnancy? No specific data; empiric adjustments based on ammonia levels recommended.
Do not administer undiluted; must be infused via central line if concentration > 0.45% potassium phosphate. Monitor serum potassium, phosphate, calcium, and magnesium. Rate of infusion should not exceed 10 mmol/h of phosphate. Risk of hypocalcemia due to phosphate precipitation. Use with caution in renal impairment.
AMMONUL (sodium phenylbutyrate) is used as a nitrogen-binding agent in urea cycle disorders. Monitor plasma ammonia levels closely; target <60 μmol/L. Administer with food to reduce GI irritation. Not recommended in patients with severe hepatic impairment due to reduced conversion to phenylacetate. Contraindicated in pregnancy (category C).
This medication is given through a vein to restore phosphate and potassium levels.,Report any signs of infusion site pain, redness, or swelling.,Inform your healthcare provider if you experience muscle cramps, weakness, numbness, or tingling.,This medication may cause low calcium levels; report symptoms such as muscle spasms or confusion.,Do not consume additional potassium or phosphate supplements unless directed by your doctor.
Take exactly as prescribed; do not skip doses.,May cause nausea, vomiting, or diarrhea; take with food.,Avoid use of valproic acid or corticosteroids unless directed.,Contact provider if symptoms of hyperammonemia occur (vomiting, lethargy, confusion).,Women of childbearing potential should use effective contraception.,Store at room temperature away from moisture.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE vs AMMONUL, answered by our medical review team.
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Phosphate supplementation to correct hypophosphatemia; acts as a buffer and is essential for cellular energy metabolism (ATP), bone mineralization, and acid-base balance.. AMMONUL is a Ammonia Detoxicant that works by Ammonul (sodium phenylacetate and sodium benzoate) provides an alternative pathway for nitrogen excretion. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Benzoate conjugates with glycine to form hippurate, which is also excreted renally. This reduces ammonia levels in patients with urea cycle disorders.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE and AMMONUL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is: IV: 2.5-5 mmol phosphate/kg body weight over 24 hours; typical dose 10-30 mmol phosphate over 4-6 hours; do not exceed 60 mmol phosphate/day.. The standard adult dose of AMMONUL is: For acute hyperammonemia: 2.5 g/m² IV over 90 minutes, followed by continuous IV infusion at 2.5 g/m² over 24 hours. For maintenance: 2.5 g/m² IV or oral every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE and AMMONUL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE is classified as Category A/B. FDA Pregnancy Category C. No adequate studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second/third trimesters: may cause hypocalce. AMMONUL is classified as Category C. Pregnancy Category C. No adequate human studies; in animal studies, sodium phenylacetate/sodium benzoate caused fetal toxicity at maternally toxic doses. First trimester: potential. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.